Clinical Trial Update: Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure [Phase 3]

View source ↗

Summary

A Phase 3 trial is investigating continued empagliflozin therapy in patients with acute decompensated heart failure who are already on active SGLT2 inhibitor tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure

Drugs mentioned

• Empagliflozin (empagliflozin)
• Jardiance (empagliflozin)

Snippet

Sponsor: Christian Schulze | Conditions: Acute Decompensated Heart Failure (ADHF) | Phase 3 | Status: RECRUITING